
    
      The secondary objectives of the study include determination of the absolute bioavailability
      of CDP6038 given via sc administration compared with iv infusion; assessment of the
      immunogenicity potential of single dose CDP6038 and assessment, on an exploratory basis, of
      other relevant systemic biomarkers and changes in clinical response.
    
  